Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: On the road to individualized treatment

Cancer Genomics and Proteomics

Volumn 4, Issue 3, 2007, Pages 135-146

  Abramovitz, Mark ^a   Leyland Jones, Brian ^b  

^a VM Institute of Research   (Canada)

^b EMORY UNIVERSITY   (United States)

Author keywords

Array CGH; Breast cancer; DASL assay; DNA copy number alterations; Epigenetics; Methylation; Microarrays; Review; SNPs; Targeted therapies

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE DERIVATIVE; AZACITIDINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; ERLOTINIB; FORMALDEHYDE; PARAFFIN; TRASTUZUMAB; VORINOSTAT;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER SURGERY; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DRUG APPROVAL; DRUG INHIBITION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOMICS; HUMAN; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE FIXATION; UNITED STATES;

EID: 34249286270     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma. Med Lett Drugs Ther 49: 23-24, 2007.
2. Abrahamsen HN, Steiniche T, Nexo E, Hamilton-Dutoit SJ and Sorensen BS: Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptasepolymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J Mol Diagn 5: 34-41, 2003.
3. Abramovitz M and Leyland-Jones B: A systems approach to clinical oncology: focus on breast cancer. Proteome Sci 4: 5, 2006.
4. Al Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Kochli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R and Sauter G: Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540, 2004.
5. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, Magnusdottir DN, Ghosh S, Agnarsson K, Birgisdottir B, Le Roux L, Olafsdottir A, Blondal T, Andresdottir M, Gretarsdottir OS, Bergthorsson JT, Gudbjartsson D, Gylfason A, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Balter K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gronberg H, Catalona WJ, Einarsson GV, Barkardottir RB, Gulcher JR, Kong A, Thorsteinsdottir U and Stefansson K: A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 652-658, 2006.
6. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL and Pollack JR: Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45: 1033-1040, 2006.
7. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, Doucet D, Thomas NJ, Wang Y, Vollmer E, Goldmann T, Seifart C, Jiang W, Barker DL, Chee MS, Floros J and Fan JB: High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16: 383-393, 2006.
8. Bibikova M, Talantov D, Chudin E, Yeakley JM, Chen J, Doucet D, Wickham E, Atkins D, Barker D, Chee M, Wang Y and Fan JB: Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. Am J Pathol 165: 1799-1807, 2004.
9. Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van't Veer LJ and Piccart M: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 3: 540-551, 2006.
10. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F and Piccart MJ: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192, 2006.
11. Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC and Hankinson SE: Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14: 2335-2339, 2005.
12. Collins C, Rommens JM, Kowbel D, Godfrey T, Tanner M, Hwang SI, Polikoff D, Nonet G, Cochran J, Myambo K, Jay KE, Froula J, Cloutier T, Kuo WL, Yaswen P, Dairkee S, Giovanola J, Hutchinson GB, Isola J, Kallioniemi OP, Palazzolo M, Martin C, Ericsson C, Pinkel D, Albertson D, Li WB and Gray JW: Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 95: 8703-8708, 1998.
13. Dawood S and Leyland-Jones B: Pharmacology and pharmacogenetics of chemotherapeutic agents. In: Breast Cancer: Translational Therapeutic Strategies. Lyman G, Burnstein H (eds.), pp. 45-56, 2007.
14. De V, I, Hankinson SE, Colditz GA and Hunter DJ: A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 63: 5236-5238, 2003.
15. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298, 2007.
16. Fan JB, Yeakley JM, Bibikova M, Chudin E, Wickham E, Chen J, Doucet D, Rigault P, Zhang B, Shen R, McBride C, Li HR, Fu XD, Oliphant A, Barker DL and Chee MS: A versatile assay for high-throughput gene expression profiling on universal array matrices. Genome Res 14: 878-885, 2004.
17. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH and Nephew KP: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66: 11954-11966, 2006.
18. Finke J, Fritzen R, Ternes P, Lange W and Dolken G: An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. Biotechniques 14: 448-453, 1993.
19. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D and Albertson DG: Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6: 96, 2006.
20. Godfrey TE, Kim SH, Chavira M, Ruff DW, Warren RS, Gray JW and Jensen RH: Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5′ nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn 2: 84-91, 2000.
21. Gunderson KL, Steemers FJ, Lee G, Mendoza LG and Chee MS: A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 37: 549-554, 2005.
22. Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW and Hunter DJ: The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 62: 1045-1049, 2002.
23. Haiman CA, Hankinson SE, Spiegelman D, De V, I, Colditz GA, Willett WC, Speizer FE and Hunter DJ: A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87: 204-210, 2000.
24. Han J, Hankinson SE, Zhang SM, De VI and Hunter DJ: Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk. Cancer Epidemiol Biomarkers Prev 13: 520-524, 2004.
25. Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW and Noh DY: Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 6: 92, 2006.
26. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC and Zochbauer-Muller S: Down-regulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat, 2007.
27. Huang TH, Perry MR and Laux DE: Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8: 459-470, 1999.
28. Ishibe N, Hankinson SE, Colditz GA, Spiegelman D, Willett WC, Speizer FE, Kelsey KT and Hunter DJ: Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. Cancer Res 58: 667-671, 1998.
29. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
30. Jing F, Zhang J, Tao J, Zhou Y, Jun L, Tang X, Wang Y and Hai H: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie 30: 14-19, 2007.
31. Johnson NA, Hamoudi RA, Ichimura K, Liu L, Pearson DM, Collins VP and Du MQ: Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells. Lab Invest 86: 968-978, 2006.
32. Joosse SA, van Beers EH and Nederlof PM: Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material. BMC Cancer 7: 43, 2007.
33. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A and Pasche B: TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 21: 3236-3243, 2003.
34. Kim C, Bryant J, Horne Z, Geyer CE, Wickerham DL, Wolmark N and Paik S: Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests proapoptotic function of dysregulated cMYC in vivo. San Antonio Breast Cancer Symposium 46. 2005. Ref Type: Abstract
35. Little SE, Vuononvirta R, Reis-Filho JS, Natrajan R, Iravani M, Fenwick K, Mackay A, Ashworth A, Pritchard-Jones K and Jones C: Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics 87: 298-306, 2006.
36. Loo LW, Grove DI, Williams EM, Neal CL, Cousens LA, Schubert EL, Holcomb IN, Massa HF, Glogovac J, Li CI, Malone KE, Daling JR, Delrow JJ, Trask BJ, Hsu L and Porter PL: Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 64: 8541-8549, 2004.
37. Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Hofler H, Kiechle M, Klijn JG, Schmitt M, Maier S and Foekens JA: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65: 4101-4117, 2005.
38. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC and Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127, 2004.
39. Park K, Kwak K, Kim J, Lim S and Han S: c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol 36: 634-639, 2005.
40. Perou CM, Jeffrey SS, van de RM, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO and Botstein D: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217, 1999.
41. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO and Botstein D: Molecular portraits of human breast tumors. Nature 406: 747-752, 2000.
42. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW and Albertson DG: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20: 207-211, 1998.
43. Press MF, Bernstein L, Sauter G, Zhou JY, Eiermann W, Pienkowski T, Crown J, Robert N, Bee V, Taupin H, Villalobos, I, Seelig S, Pegram M and Slamon DJ: Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium, 2005. Ref Type: Abstract
44. Reichmuth C, Markus MA, Hillemanns M, Atkinson MJ, Unni KK, Saretzki G and Hofler H: The diagnostic potential of the chromosome translocation t(2;13) in rhabdomyosarcoma: a Per study of fresh-frozen and paraffin-embedded tumor samples. J Pathol 180: 50-57, 1996.
45. Richard F, Pacyna-Gengelbach M, Schluns K, Fleige B, Winzer KJ, Szymas J, Dietel M, Petersen I and Schwendel A: Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 89: 305-310, 2000.
46. Ross JS and Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16: 413-428, 1998.
47. Rupp GM and Locker J: Purification and analysis of RNA from paraffin-embedded tissues. Biotechniques 6: 56-60, 1988.
48. Sheils OM and Sweeney EC: TSH receptor status of thyroid neoplasms - TaqMan RT-PCR analysis of archival material. J Pathol 188: 87-92, 1999.
49. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP and Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170, 2007.
50. Shimada M, Imura J, Kozaki T, Fujimori T, Asakawa S, Shimizu N and Kawaguchi R: Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. Oncol Rep 13: 633-641, 2005.
51. Slamon DJ, Eiermann W, Pienkowski T, Martin M, Pawlicki M, Chan M, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram MD, Press M and Crown J: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BGIRG 006 study. SABCS, 2005. Ref Type: Abstract.
52. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP and Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
53. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003.
54. Specht K, Richter T, Muller U, Walch A, Werner M and Hofler H: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158: 419-429, 2001.
55. Stanta G and Bonin S: RNA quantitative analysis from fixed and paraffin-embedded tissues: membrane hybridization and capillary electrophoresis. Biotechniques 24: 271-276, 1998.
56. Tanner MM, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray JW, Kallioniemi OP and Isola J: Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1: 1455-1461, 1995.
57. Tokunaga E, Oki E, Kimura Y, Yamanaka T, Egashira A, Nishida K, Koga T, Morita M, Kakeji Y and Maehara Y: Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat 101: 249-257, 2007.
58. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH and Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002.
59. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der KK, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
60. Wang Z, Yan P, Potter D, Eng C, Huang TH and Lin S: Heritable clustering and pathway discovery in breast cancer integrating epigenetic and phenotypic data. BMC Bioinformatics 8: 38, 2007.
61. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ and Thomas G: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet, 2007.
62. Yeon CH and Pegram MD: Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 23: 391-409, 2005.
63. Yoshimoto M, Cutz JC, Nuin PA, Joshua AM, Bayani J, Evans AJ, Zielenska M and Squire JA: Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intraepithelial neoplasias. Cancer Genet Cytogenet 169: 128-137, 2006.